What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials-Reference-Cited by-同舟云学术

What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials

Published:2021-09-22 Issue:11 Volume:73 Page:2059-2068
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Furie Richard¹^ORCID,Morand Eric F.²^ORCID,Bruce Ian N.³,Isenberg David⁴^ORCID,Vollenhoven Ronald⁵,Abreu Gabriel⁶,Pineda Lilia⁷,Tummala Raj⁷

Affiliation:

1. Zucker School of Medicine at Hofstra/Northwell Great Neck New York

2. Monash University Melbourne Victoria Australia

3. University of Manchester NIHR Manchester Biomedical Research Centre Manchester University Hospitals NHS Foundation Trust Manchester Academic Health Science Centre Manchester UK

4. University College London and University College Hospital London UK

5. Amsterdam Rheumatology and Immunology Center Amsterdam The Netherlands

6. BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

7. BioPharmaceuticals R&D, AstraZeneca Gaithersburg Maryland

Funder

AstraZeneca

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41778

Reference44 articles.

1. US Food and Drug Administration.Systemic lupus erythematosus–developing medical products for treatment. June2010. URL:https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/systemic‐lupus‐erythematosus‐developing‐medical‐products‐treatment.

2. Novel evidence-based systemic lupus erythematosus responder index

3. Systemic Lupus Erythematosus Disease Activity Index 2000;Gladman DD;J Rheumatol,2002

4. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus

5. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: A qualitative study in Denmark;Lupus;2024-06-20

2. New and emerging therapies for systemic lupus erythematosus;Clinical Immunology;2024-06

3. Correction: Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice;RMD Open;2024-04

4. Microsimulation model of the cost-effectiveness of anifrolumab compared to belimumab in the United Arab Emirates;Journal of Medical Economics;2024-03-06

5. Should we be targeting type 1 interferons in antiphospholipid syndrome?;Clinical Immunology;2023-10